Analyzing Fulgent Genetics (NASDAQ:FLGT) and EUDA Health (NASDAQ:EUDA)

EUDA Health (NASDAQ:EUDA) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, risk, analyst recommendations, earnings and institutional ownership.

Profitability

This table compares EUDA Health and Fulgent Genetics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
EUDA Health	N/A	N/A	N/A
Fulgent Genetics	-23.04%	-3.24%	-2.97%

Valuation and Earnings

This table compares EUDA Health and Fulgent Genetics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
EUDA Health	$6.82 million	5.29	-$2.77 million	N/A	N/A
Fulgent Genetics	$322.67 million	1.85	-$60.51 million	($2.39)	-8.81

EUDA Health has higher earnings, but lower revenue than Fulgent Genetics.

Volatility & Risk

EUDA Health has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500. Comparatively, Fulgent Genetics has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for EUDA Health and Fulgent Genetics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
EUDA Health	1	1	1	0	2.00
Fulgent Genetics	1	2	2	0	2.20

EUDA Health currently has a consensus target price of $55.00, indicating a potential upside of 355.86%. Fulgent Genetics has a consensus target price of $27.00, indicating a potential upside of 28.21%. Given EUDA Health’s higher probable upside, analysts plainly believe EUDA Health is more favorable than Fulgent Genetics.

Institutional & Insider Ownership

4.3% of EUDA Health shares are owned by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are owned by institutional investors. 36.2% of Fulgent Genetics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

About EUDA Health

EUDA Health Holdings Limited operates as a healthcare specialty company. The company operates through two segments, Medical Services and Property Management Services. It offers a range of specialty care services to patients; and operates medical facility general practice clinic that provides holistic care for various illnesses. The company is also involved in the property management that services shopping malls, business office building, or residential apartments. EUDA Health Holdings Limited is headquartered in Singapore.

About Fulgent Genetics

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.